Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Several new medications for kidney cancer have been approved in recent years.
Recommendations from The National Foundation for Cancer Research
Cancer screenings have dropped precipitously due to the COVID-19 pandemic.
University of Colorado Cancer Center member Martin McCarter, MD, is investigating a new treatment sequence for esophageal cancer.
Lumakras led to tumor shrinkage in 36% of NSCLC patients with KRAS G12C mutations.
New targeted therapy shrank tumors in nearly a quarter of patients with bile duct cancer.
Rybrevant is the first treatment for people with advanced non-small-cell lung cancer whose tumors have EGFR exon 20 insertion mutations.
Braftovi plus Erbitux improved survival for people with previously treated advanced colorectal cancer.
The same therapies having an impact in advanced melanoma have a comparable impact in eradicating microscopic deposits of residual disease.
Opdivo plus chemotherapy led to a significant improvement in overall survival.
The antibody-drug conjugate shrank tumors in 28% of people with locally advanced or metastatic urothelial cancer.
The monoclonal antibody reduces the risk of disease progression or death by 45%.
More than 70% of people treated with Abecma, a customized immunotherapy, experienced complete or partial remission.
Acupuncture was associated with a steeper and more sustained reduction in chronic pain for cancer survivors than pain medications.
The kinase inhibitor delayed disease progression by 27% for people who had tried at least two prior therapies.
People with head and neck cancer who are worried about the cost of treatment are about twice as likely to die as people who are not.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.